NCT02426983 is a Phase 1/Phase 2 clinical trial of Direct Current Stimulation in Schizophrenia, sponsored by University of Ottawa.

Who is sponsoring NCT02426983?

NCT02426983 is sponsored by University of Ottawa.

What drugs are being tested in NCT02426983?

Interventions in NCT02426983: Direct Current Stimulation, Dextromethorphan.

What condition does NCT02426983 study?

NCT02426983 studies Schizophrenia.

Is NCT02426983 still recruiting?

NCT02426983 is currently status unknown. Last updated 21 April 2015.

Last reviewed 2015-04-21 · How we verify

NCT02426983

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Auditory Sensory Memory Processing

Status unknown Phase 1/Phase 2 Last updated 21 April 2015

What this trial tests

Phase 1/Phase 2 trial testing Direct Current Stimulation in Schizophrenia in 12 participants. Status unknown.

Timeline

1 April 2015

Primary endpoint
1 September 2015

1 April 2016

Quick facts

Lead sponsor	University of Ottawa
Phase	Phase 1/Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Enrollment	12
Start date	1 April 2015
Primary completion	1 September 2015
Estimated completion	1 April 2016
Sites	1 location across Canada

Drugs / interventions tested

Direct Current Stimulation
Dextromethorphan — full drug profile →

Conditions studied

Schizophrenia — all drugs for Schizophrenia →

Sponsor

University of Ottawa

Who can join

Adults 18 to 35, any sex, with Schizophrenia. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

MMN ERP amplitudes as a measure of sensory processing changes
Time frame: 1 year
Acute effects of DMO (vs. placebo) and tDCS (vs. sham) on MMN-indexed auditory sensory memory processing
Adverse Events Scores as measure of treatment side effects
Time frame: 1 year
Adverse Events and self-reported symptoms after treatment

Sponsor's own description

Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a very weak constant current to temporarily excite the brain area of interest via small electrodes placed on the scalp. Currently, tDCS is being used as a tool to investigate mental processes (cognition) and motor function (movement) in healthy controls and to treat neurological (i.e. stroke) and psychiatric (i.e. depression and dementia) patients. tDCS has been found to improve motor processes and cognitive performance, including attention and memory functions. This study will attempt to examine the effects of tDCS on a specific aspect of short term memory to sounds measured from electrical activity (EEG) from the top of the scalp. This study will also assess the effect of a drug, dextromethorphan (DMO), commonly found in cough syrup, which is thought to regulate tDCS treatment through brain receptors. The study involves four laboratory test sessions. EEG assessments will be done in two sessions involving 'anodal' tDCS stimulation (to temporarily excite cortical activity locally), one session with DMO treatment and one with placebo treatment, and two sessions involving 'sham' tDCS stimulation (device is turned off), with the same DMO and placebo treatments. These findings will contribute to our understanding of the brain chemistry involved in tDCS treatment and its effects on cognitive abilities.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Direct Current Stimulation

Trials testing the same drug.

NCT04117256 — Transcranial Versus Suboccipital Direct Current Stimulation · NA · completed

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other University of Ottawa trials

Trials by the same sponsor.

NCT07459465 — Postprandial Triglyceride Concentrations Across Menstrual Cycle Phases · NA · not yet recruiting
NCT07261202 — Impact of Indoor Overheating on Physiological Strain in Children · NA · recruiting
NCT07383324 — Heat Stress in Individuals With Schizophrenia · NA · recruiting
NCT07267598 — Suitability of a 26 °C Indoor Environment for Mitigating Heat Strain in Young Adults · NA · recruiting
NCT07189507 — Suitability of the 26 °C Indoor Temperature Upper Limit for Older Adults: Impacts of Clothing and Daily Activity · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02426983 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Ottawa
Last refreshed: 21 April 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02426983.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing